On March 5, U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, announced his resignation, effective in April.
“It was a very hard decision. This is the best job I will ever have,” Dr. Gottlieb said in an interview with The Washington Post, adding that he is leaving the position to spend more time with his family. “I get home late Friday, work on weekends, and come back to Washington on Sunday. I did the job 100 percent.”
The resignation came as a surprise to many officials. Dr. Gottlieb has held the position of commissioner since 2017 and has prioritized the approval of generic drugs to lower drug prices and tackling public health issues like opioid addiction and youth vaping during his tenure.
On March 7, the FDA announced that Ned Sharpless, MD, the current director of the National Cancer Institute, will serve as acting commissioner of the FDA. Dr. Sharpless is expected to start in this position in the coming weeks as the search for a permanent replacement for Dr. Gottlieb begins.